Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2846765 | 0.97 | KEAP1 (0.42) | KEAP1NFE2L2CES2CES1EPHX1 | |
| SCHEMBL873007 | 0.97 | KEAP1 (0.42) | KEAP1NFE2L2CES2CES1EPHX1 | |
| SCHEMBL19716029 | 0.84 | KEAP1 (0.39) | KEAP1NFE2L2 | |
| SCHEMBL2848328 | 0.77 | CES2 (0.35) | KEAP1NFE2L2CES2CES1EPHX1 | |
| SCHEMBL8395889 | 0.76 | CES2 (0.36) | KEAP1NFE2L2CES2CES1EPHX1 | |
| SCHEMBL11423542 | 0.74 | KEAP1 (0.33) | KEAP1NFE2L2CES2CES1 | |
| SCHEMBL2848230 | 0.74 | KEAP1 (0.33) | KEAP1NFE2L2CES2CES1EPHX1 | |
| SCHEMBL8328164 | 0.74 | KEAP1 (0.42) | KEAP1NFE2L2CES2CES1EPHX1 | |
| SCHEMBL2846763 | 0.74 | CES2 (0.39) | KEAP1NFE2L2CES2CES1EPHX1 | |
| SCHEMBL2848234 | 0.74 | EPHX1 (0.37) | KEAP1NFE2L2CES2CES1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217204-B2 | Catalyst for asymmetric hydrogenation | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-07-10 | — | — | US | claimed |
| EP-2438989-B1 | USE OF ASYMMETRIC HYDROGENATION CATALYST | TAKASAGO PERFUMERY CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-9061959-B2 | Method for manufacturing optically active menthol | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-06-23 | — | — | US | disclosed |
| US-9000192-B2 | Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-04-07 | — | — | US | disclosed |
| EP-2646150-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | Takasago International Corporation (JP) | 2013-10-09 | — | — | EP | disclosed |
| EP-2647616-A1 | METHOD FOR MANUFACTURING OPTICALLY ACTIVE MENTHOL | Takasago International Corporation (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-20130253228-A1 | METHOD FOR MANUFACTURING OPTICALLY ACTIVE MENTHOL | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-09-26 | — | — | US | disclosed |
| US-20130217895-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-08-22 | — | — | US | disclosed |
| EP-2543437-A2 | HOMOGENEOUS ASYMMETRIC HYDROGENATION CATALYST | Takasago International Corporation (JP) | 2013-01-09 | — | — | EP | disclosed |
| US-8217204-B2 | Catalyst for asymmetric hydrogenation | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| WO-2012074128-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-06-07 | — | — | WO | disclosed |
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | H1-0, H1-5, ADH5 | KEAP1 149/4885NFE2L2 55/4885CES2 2014/4885 |
| US-20130217895-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | HMOX1, NQO1, CBR3 | KEAP1 82/4885NFE2L2 46/4885CES2 1807/4885 |
| US-20130253228-A1 | METHOD FOR MANUFACTURING OPTICALLY ACTIVE MENTHOL | MSMO1, GGPS1, MAN1B1 | KEAP1 156/4885NFE2L2 529/4885CES2 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.